Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects
Crossref DOI link: https://doi.org/10.1007/s40262-017-0522-8
Published Online: 2017-02-25
Published Print: 2017-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Huntjens, Dymphy R. H.
Ouwerkerk-Mahadevan, Sivi
Brochot, Anne
Rusch, Sarah
Stevens, Marita
Verloes, Rene
Funding for this research was provided by:
Janssen Pharmaceutica NV, Belgium.
License valid from 2017-02-25